Five days of oral topotecan (Hycamtin®), a phase I and pharmacological study in adult patients with solid tumours

European Journal of Cancer

Volumn 34, Issue 7, 1998, Pages 1030-1035

  Gerrits, C J H ^a   Burris, H ^b   Schellens, J H M ^a   Planting, A S T ^a   Van Den Burg, M E L ^a   Rodriguez, G I ^b   Van Beurden, V ^a   Loos, W J ^a   Hudson, I ^c   Fields, S ^c   Verweij, J ^a   Von Hoff, D D ^b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c NONE

Author keywords

Pharmacokinetics; Phase I; Topoisomerase I; Topotecan

Indexed keywords

DNA TOPOISOMERASE; TOPOTECAN;

ABDOMINAL DISCOMFORT; ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG HALF LIFE; DRUG TOLERANCE; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; FEMALE; GRANULOCYTOPENIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIFE EXPECTANCY; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT PLANNING; VOMITING; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANOREXIA; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FATIGUE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; TOPOTECAN; TREATMENT OUTCOME;

EID: 0032101820     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10173-3     Document Type: Article

References (42)

1. Kingsburry WD, Boehm JC, Jakas DR, et al. Synthesis of water soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 1991, 34, 98-107.
2. Champoux J. Evidence from an intermediate with a single strand break in the reaction catalyzed by the DNA un-twisting enzyme. Proc Natl Acad Sci USA. 73:1976;3488-3491.
3. Camilloni G, Di Martino E, Caserta M, et al. Eukaryotic DNA topoisomerase I is topology dependent. Nucleic Acids Res 1988, 16, 7071-7085.
4. Camilloni G, Di Martino E, Di Mauro E, et al. Regulation of the function of eukaryotic DNA topoisomerase I: topological conditions for inactivity. Proc Natl Acad Sci USA 1989, 86, 3080-3084.
5. Muller M. Quantitation of eukaryotic topoisomerase I reactivity with DNA. Preferential cleavage of supercoiled DNA. Biochem Biophys Acta. 824:1985;263-267.
6. Muller M, Pfund W, Metha V, et al. Eukaryotic type I isomerase is enriched in the nucleolus and catalytically active on ribosomal DNA. EMBO J 1985, 4, 1237-1243.
7. Hsiang YH, Hertzberg R, Hecht S, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985, 260, 14873-14878.
8. Hsiang Y.H., Liu L.F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48:1988;1722-1726.
9. Rowinsky EK, Grochow LB, Hendricks CB, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992, 10, 647-656.
10. Van Warmerdam LJC, Verweij J, Schellens JHM, et al. Pharmacokinetics and pharmacodynamics of topotecan administered in a daily times five regimen every three weeks. Cancer Chemother Pharmacol 1995, 35, 237-245.
11. Verweij J, Lund B, Beijnen JH, et al. Phase I and pharmacokinetic study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 1993, 4, 673-678.
12. Saltz L, Sirott M, Young C, et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 1993, 85, 1499-1507.
13. Schiller JH, Kim K, Johnson D. Phase II study of topotecan in extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 1994, 13, 330 (Abstract 1093).
14. Wanders J, Ardizanni A, Hansen HH, et al. Phase II study of topotecan in refractory and sensitive small cell lung cancer (SCLC). Proc Am Assoc Cancer Res 1995, 36, 237 (Abstract 1415).
15. Kudelka A, Edwards C, Freedman R, et al. An open phase II study to evaluate the efficacy and toxicity of topotecan administered intravenously as 5 daily infusions every 21 days to women with advanced epithelial ovarian carcinoma. Proc Am Soc Clin Oncol 1993, 12, 259 (Abstract 821).
16. Armstrong D, Rowinsky E, Donehower R, et al. A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol 1995 14, 275 (Abstract 769).
17. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996, 14, 3056-3061.
18. Carmichael J, Gordon A, Malfetano J, et al. Topotecan, a new active drug vs paclitaxel in advanced epithelial ovarian carcinoma: international topotecan study group trial. Proc Am Soc Clin Oncol 1996, 15, 283 (Abstract 765).
19. Malmstrom H., Sorbe B., Simonsen E. The effect of topotecan in platinum refractory ovarian cancer. Proc Am Soc Clin Oncol. 15:1996;299.
20. Lynch TJ, Kalish L, Strauss G, et al. Phase II study of topotecan in metastatic non-small cell lung cancer. J Clin Oncol 1994, 12, 347-352, 1994.
21. Perez-Soler R, Fossella FV, Glisson BS, et al. Phase II study of topotecan in patients with advanced non-small cell lung cancer (NSCLC) previously untreated with chemotherapy. J Clin Oncol 1996, 14, 503-513.
22. Sugarman SM, Agani JA, Daugherty K, et al. A phase II trial of topotecan (TPT) for the treatment of advanced measurable colorectal cancer. Proc Am Soc Clin Oncol 1994, 13, 225 (Abstract 686).
23. Kraut EH, Stanbus A, Mayernich D, et al. Phase II trial of topotecan in metastatic malignant melanoma. Proc Am Assoc Cancer Res 1995, 36, 238 (Abstract 1420).
24. Robert F, Wheeler RH, Molthrop DC, et al. Phase II study of topotecan in advanced head and neck cancer: identification of a new active agent. Proc Am Soc Clin Oncol 1994, 13, 281 (Abstract 905).
25. Smith RE, Lew D, Rodriguez GI, et al. Evaluation of topotecan in recurrent or metastatic head and neck cancer. Proc Am Soc Clin Oncol 1996, 15, 310, (Abstract 868).
26. Ilson D, Motzer RJ, O'Moore P, et al. A phase II trial of topotecan in advanced renal cell carcinoma. Proc Am Soc Clin Oncol 1993, 12, 248 (Abstract 779).
27. Giantonio BJ, Kosierowski R, Ramsey HE. Phase II study of topotecan for hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 1993, 12, 247 (Abstract 774).
28. Noda K, Sasaki H, Yamamoto K, et al. Phase II trial of topotecan for cervical cancer of the uterus. Proc Am Soc Clin Oncol 1996, 15, 280 (Abstract 754).
29. Puc HS, Bajorin DF, Bosl GJ, et al. Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. Investig New Drugs 1995, 13, 163-165.
30. Kuhn J, Rizzo J, Eckardt J, et al. Phase I bioavailability study of oral topotecan. Proc Am Soc Clin Oncol 1995, 14, 474 (Abstract 1538).
31. Schellens JHM, Creemers GJ, Beynen JH, et al. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 1996, 73, 1268-1271.
32. Burris H, Gerrits CM, Schellens JHM, et al. Oral topotecan for 10 days once daily and twice daily every 3 weeks: a phase I and pharmacologic study in adults. Ann Oncol 1996, 7, 126 (Suppl. 5).
33. National Cancer Institute. Guidelines for Reporting of Adverse Drug Reactions. Bethesda, Division of Cancer Treatment, National Cancer Institute, 1988.
34. World Health Organisation. WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication No 40. Geneva, Switzerland, World Health Organisation, 1979.
35. Loos WJ, Stoter G, Verweij J, et al. Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and the lactone ring-opened product (hydroxy-acid) in human plasma and urine. J Chromatography B 1996, 678, 309-315.
36. Holford N.H., Scheiner L.B. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 6:1981;242-247.
37. Creemers GJ, Gerrits CJH, Eckardt JR, et al. Phase I and pharmacologic study of oral topotecan administered twice daily for 21-days to adult patients with solid tumors. J Clin Oncol 1997, 15, 1087-1093.
38. Stehlin JS, Natelson EA, Hinz HR, et al. Phase I clinical trial and pharmacokinetic results with oral administration of 20-S-camptothecin. In Potmesil M, Pinedo H, eds. Camptothecins: New Anticancer Agents. Boca Raton, CRC Press, 1995, 59-65.
39. Verschraegen CF, Natelson E, Giovanella B, et al. Phase I study of oral 9-nitro-camptothecin (9NC). Proc Am Soc Clin Oncol 1996, 15, 482 (Abstract 1532).
40. Fukuoka M., Noriyuki M. Clinical studies of irinotecan alone or in combination with cisplatin. Cancer Chemother Pharmacol. 34:1994;S105-S111.
41. Schlichenmyer WJ, Rowinsky EK, Donehower RC, et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993, 85, 271-291.
42. Creemers G.J., Lund B., Verweij J.J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treatment Rev. 20:1994;73-96.